Sudden cardiac death remains a major threat despite advances in medication and other treatments for preventing recurrent heart attacks and heart failure. Each year, it claims the lives of more than 300,000 Americans alone, and the overwhelming majority of those deaths are caused by ventricular fibrillation, or rapid, uncoordinated contractions.

Randomized trials have shown that implantable defibrillators dramatically reduce mortality in patients with a history of arrhythmias, or abnormal heart rhythms caused by ventricular fibrillation, or in patients at risk for sudden cardiac death. Implantable defibrillators currently on the market, however, are similar in form and function: titanium boxes implanted in the pectoral region. In most patients, this device creates a “cardiac bump” that is visible when not covered by loose-fitting clothes. The implant procedure typically requires hospitalization, followed by frequent device adjustments.

Founded in 2003, InnerPulse, is a privately held, early-stage company with a cutting-edge alternative to traditional electrophysiological devices. Our Intravascular Implantable Defibrillator™ (IID) represents a disruptive technology that will redefine its market category.

Unlike currently available products, InnerPulse offers a truly minimally invasive treatment, enabling cardiologists and electrophysiologists to implant the life-saving IID device within the patient’s vascular system in less than 15 minutes. Specialists will perform the implant in traditional laboratories used for other cardiac procedures. Follow-up care for both the patient and device will be simple, and the presence of the device can remain the patient’s secret.

Today the patient population of defibrillator candidates is significantly underserved. Without a defibrillator, a victim of sudden cardiac arrest has only a five-percent chance of survival. At InnerPulse, we are developing innovative technology, devices, software protocols, and procedures specifically to help these patients—to transform the treatment of cardiac arrhythmias and save thousands of lives each year.

And that’s just the beginning.

InnerPulse’s corporate officers and board of directors bring a breadth and depth of experience in technology and product development, sales, marketing, business operations, and other areas of management within the medical device industry. They have been equally successful in startup and corporate environments.

GO BACK